FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. - Zhang Y; Lu Y; Zhang C; Huang D; Wu W; Shen J; Cai Y; Chen W; Yao W (International journal of oncology, 2018)